tbuckley/cabot-search huggingface dataset:
Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
Authors: Andrew Wang, Hanna Kelly Sanoff, Autumn Jackson McRee, Bert H. O'Neil, Benjamin F. Calvo, Meliessa G. Hennessy, Curran Murphy, Maureen T. Tynan, A. William Blackstock, Edward Graeme Garmey, Joel E. Tepper
Journal: Journal of Clinical Oncology (2015)

TPS3629 Background: There is strong interest in the development of novel agents and strategies to further improve the therapeutic ratio of neoadjuvant chemoradiotherapy for rectal cancer. One innovative approach is to incorporate nanoparticle (NP) therapeutics, which are designed to preferentially accumulate in tumors. CRLX101 is an investigational nanoparticle-drug conjugate with a camptothecin payload. Preclinically, CRLX101 has been shown to be a potent radiosensitizer in colorectal cancer. The purpose of this Phase IB/II study is to assess tolerability and to evaluate whether the addition of CRLX101 to capecitabine and radiotherapy can improve pathologic complete response (pCR) and clinical outcomes for rectal cancer. Methods: This ongoing open label, single-arm multicenter Phase Ib/II study is designed to evaluate the addition of CRLX101 to a standard 5FU-based chemoradiotherapy regimen in patients with locally advanced rectal carcinoma (stage cT3-4N0 or cT1-4N+). Phase Ib employed a 3+3 dose escalation design with starting dose of 12 mg/m2. Dose level +1 was 15 mg/m2, the MTD for single agent CRLX101. 8 patients have completed treatment without DLT (3 in cohort 1 and 5 in cohort 2) and 1 patient is undergoing treatment at the 15mg/m2 dose level. We have identified 15mg/m2 as the MTD /RP2D. The Phase II portion of the study is ongoing and will evaluate the efficacy of this MTD/RP2D and further characterize the safety of CRLX101 combined with CRT. Patients in the Phase Ib portion with resectable disease and who were treated at the RP2D will be included in the Phase II study population for efficacy analysis. Target accrual is 53 evaluable patients in the Phase II trial and a primary endpoint of pCR rate will be evaluated using a Simon two-stage design. Secondary objectives include evaluation of pathological response, disease free survival (DFS) and overall survival (OS). We hypothesize that our proposed regimen will improve the rate of pCR compared to 15-20% historical benchmarks. If results are consistent with a pCR rate of at least 35%, the treatment regimen will be considered worthy of further investigation. Clinical trial information: NCT02010567. Clinical trial information: NCT02010567.
A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated stage III or IV, low-grade CLL
Authors: D. W. Nyman, R. Mena, R. Robles, M. Auerbach, L. Pandit
Journal: Journal of Clinical Oncology (2006)

6606 Background: The decision to treat indolent CLL is often based on progressive bulky disease, worsening symptoms, and increasing hematological derangement. When treatment is indicated, these lymphoproliferative disorders are sensitive to combination immunochemotherapies utilizing pentostatin (P), a purine analog, cyclophosphamide (C), a DNA alkylator, and rituximab (R), a potent anti-CD20 monoclonal antibody. P+C+R represents a promising new approach in the treatment of patients with low grade CLL. Methods: Eligibility criteria allow previously treated and treatment-naïve patients diagnosed with low-grade stage III/IV CLL (modified Rai classification). Treatment consisted of intravenous infusions of P (4 mg/m 2 ), C (600 mg/m 2 ), and R (375 mg/m 2 ) on day 1 of a 21-day cycle for a total of 8 cycles. Clinical evaluation (including CT scan) was performed after cycles 2, 4, 6, and 8. Patients were stratified by disease and by prior treatment status. Results: The intent-to-treat (ITT) population consisted of 41 CLL patients (median age 64, range 36–85) who received a total of 207 cycles (median 4 per patient). ECOG status at enrollment was 0 (66%), 1 (27%) and 2 (7%). The overall response rate was 61% (CR 13%, PR 48%). One grade 4 neutropenia was documented. Four deaths have been recorded. An 81 YO patient was hospitalized 8 days after cycle 1; death, due to sepsis, occurred 22 days later. The death of an 83 YO was reported 10 days after cycle 2 as a result of an acute MI. An 83 YO patient, who developed gastroenteritis, was hospitalized 10 days after cycle 2. This progressed to dehydration and atrial flutter. Death came as a result of pulmonary edema and ASHD. An 82 YO man was hospitalized 4 days after completing cycle 2. He presented with extreme dyspnea but cause of death was CLL. Conclusions: This immunochemotherapeutic regimen is active in Grade III/IV CLL and the incidence of significant toxicities was low with deaths occurring only in elderly (&gt;80 YO) patients. Updated results of this trial will be presented at the ASCO meeting. No significant financial relationships to disclose.
"Microwave," Not "Electric Ray" Oven.
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
Authors: Andreas Hochhaus, Maria Teresa Gómez Casares, Jesper Stentoft, Eibhlin Conneally, Valentin García-Gutiérrez, Norbert Gattermann, Wieslaw Wiktor-Jedrzejczak, Philipp D. Le Coutre, Bruno Martino, Susanne Saussele, Francis J. Giles, Jerald P. Radich, David M. Ross, Hans D. Menssen, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, Veronique Bedoucha, Giuseppe Saglio
Journal: Blood (2016)
MANGANESE TOXICOSIS
Authors: R. VON JAKSCH
Journal: JAMA (1913)

From the paper of L. Casamajor<sup>1</sup>I learn that in the mines and factories of America cases of manganese toxicosis occur not infrequently; cases such as have been described, first, in 1823, by Couper; in 1901 by myself<sup>2</sup>and Embden and then by Friedel. That induces me to communicate briefly to my American colleagues my clinical observations in connection with that interesting and well-known morbid state. I think that the nervous affections among workmen in factories who are occupied with the production of potassium permanganate and among workmen in mills who are working in an atmosphere full of dust of manganates and in workmen in manganese mills, are produced through the inspiration of dust containing manganates. I reach that conclusion from the circumstance that in the factory from which I gathered my observations, after the spread of dust had been prevented, the workmen were thenceforth free from such affections. The
Androgen receptor in human liver: Characterization and quantitation in normal and diseased liver
Authors: P Eagon
Journal: Hepatology (1994)

Liver is responsive to sex hormones. The role of androgens in normal human liver function is not well understood, although androgens have been implicated in several liver diseases. Because the human hepatic androgen receptor has not been adequately characterized, we analyzed cytosolic and nuclear fractions from normal human liver of both sexes for androgenbinding activity using multipoint saturation analysis with the androgenic radioligand methyltrienelone (R1881). Both cytosolic and nuclear fractions of both sexes displayed high affinity R1881 binding (dissociation constants = nanomolar range). The R1881 binding in both fractions is highly specific in that potent androgens compete well, and the antiandrogens hydroxyflutamide and cyproterone acetate show partial competition; other nonandrogenic steroid hormones do not compete. The cytosolic R1881 receptor displays physicochemical characteristics of androgen receptors in other tissues in that it is retained by heparin-Sepharose and by DNA cellulose after activation, and it displays a molybdate-stabilized 8S form on sucrose gradients and a 7.3-nm species on gel filtration chromatography. Receptor activity was also quantitated in specimens of hepatic adenoma, focal nodular hyperplasia and metastatic carcinoma to the liver and in samples of adjacent histologically normal specimens when available. In general, both the diseased and normal portions of the livers from the patients with hepatic adenoma and metastatic carcinoma to the liver, but not focal nodular hyperplasia, demonstrated reduced total androgen-receptor activity as compared with liver from normal individuals. However, in the tumor-containing specimens from all three liver diseases, the nuclear receptor (i.e., the biologically active form) represented a higher proportion of the total receptor activity than was evidenced in either the normal adjacent specimens or liver from normal individuals. This finding suggests that these tumors may differ from normal liver in their responses to androgens. (Hepatology 1994;19:92-100).
The delusive dichotomy
Authors: C. D. Aring
Journal: JAMA (1976)

IN AN article entitled "Thoughts on Teaching Medicine," Sir Robert Platt<sup>1</sup>said: ... After being taught... not to trust any evidence except that based on the measurements of physical science, the student has to find out for himself that all important decisions are in reality made, almost at an unconscious level, by that most perfect and complex of computers the human brain.... And the data are mostly not of the hard crude type with which that simple fellow the scientist has to deal, but are of a much more subtle, human, and interesting character, each tinted in its own colors of personality and emotion. All this the student has to discover for himself while his teachers strangely pretend to believe that the secrets of medicine are revealed only to those whose biochemical background is beyond reproach. Those subscribing to Platt's statement are likely to be uneasy with the austerity of
Informed consent: ethical, legal, and medical implications for doctors and patients who participate in randomised clinical trials.
Authors: Carolyn Faulder, M Peckham, M Baum, J Bullimore, J Cuzick, G Maguire, J Sloane, C Teasdale, J Tobias
Journal: BMJ (1983)

Since Austin Bradford Hill's seminal paper on medical ethics and controlled trials 20 years ago' the issue of informed consent, particularly as it relates to controlled clinical trials, has not attracted much public attention in British medical practice.In 1982, however, the coroner at an inquest on an elderly woman expressed the view that "the whole idea of concealed controlled trials [should] be brought to the public notice for proper discussion."The patient, who had cancer of the bowel, died two weeks after having been entered as an unwitting participant into a randomised clinical trial testing the efficacy of a new drug treatment.For the past two years the Cancer Research Campaign Working Party in Breast Conservation has been devising a protocol for a trial in "early" breast cancer designed to determine whether local tumour excision, with breast conservation plus radical radiotherapy, gives results comparable with simple mastectomy plus radical radiotherapy in terms of recurrence and survival.2This trial has now been accepted for funding by the Cancer Research Campaign and was launched on 18 November 1982.Throughout the planning period, the question of informed consent was under constant discussion.It was agreed from the outset that a large number of patients (about 2000) would have to be entered into the trial so that it would be sensitive enough to detect differences in therapeutic
Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation—Reply
Authors: Eric L. Eisenstein, David F. Kong, Kevin J. Anstrom, Robert M. Califf
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Polymyalgia Rheumatica.
Authors: Kenneth R. Wilske
Journal: Annals of Internal Medicine (1967)

s1 May 1967Polymyalgia Rheumatica.Kenneth R. Wilske, M.D., L. A. Healey, M.D. (Associate)Kenneth R. Wilske, M.D.Search for more papers by this author, L. A. Healey, M.D. (Associate)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-5-1069_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe clinical and laboratory features of 18 patients with the syndrome of polymyalgia rheumatica seen in an 18-month period are reviewed. The average age of the patients was 68 years; 17 were women. All had proximal muscle pain and tenderness and a high erythrocyte sedimentation rate (mean of 102 mm/hr). Fever, anemia, and malaise were common. All these findings were rapidly reversed by corticosteroid therapy. A small maintenance dose was frequently needed for continued suppression of the illness.No patient had rheumatoid factor, antinuclear factors, or elevated muscle enzymes in the serum. None have developed arthritis, malignancy, or other disease... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Seattle, Washington PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByIron-Restricted Erythropoiesis in Anaemic Patients with Giant Cell Arteritis and Polymyalgia Rheumatica 1 May 1967Volume 66, Issue 5Page: 1069-1069KeywordsArthritisClinical laboratoriesCorticosteroid therapyEnzymesErythrocyte sedimentation rateFeversMusclesMyalgiaPolymyalgia rheumaticaResearch laboratories Issue Published: 1 May 1967 PDF DownloadLoading ...
Perfusion of the Wedged Pulmonary Artery Catheter as Method of Assessing Pulmonary Vasomotion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wrong Address
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Author Index Vol. 70, 2001
Authors: Jean Cottraux, Ivan Note, Sai Nan Yao, Sylviane Lafont, Brigitte Note, Evelyne Mollard, Martine Bouvard, Alain Sauteraud, Marc Bourgeois, Jean-François Dartigues, Gieta van der Pompe, Michael H. Antoni, Hugo J. Duivenvoorden, Alexander de Graeff, R.F.A. Simonis, Sytze G.L. van der Vegt, Cobi J. Heijnen, Eamonn Ferguson, Giovanni A. Fava, Fedra Ottolini, Nicoletta Sonino, Valdo Ricca, Edoardo Mannucci, Barbara Mezzani, Sandra Moretti, Milena Di Bernardo, Marco Bertelli, Carlo M. Rotella, Carlo Faravelli, Ludwig Teusch, Hildegard Böhme, Jobst Finke, Markus Gastpar
Journal: Psychotherapy and Psychosomatics (2001)
Incorrect Affiliations for Author
Journal: JAMA Internal Medicine (2016)

Michaël Chassé, MD, PhD, FRCPC; Alan Tinmouth, MD, MSc, FRCPC; Shane W. English, MD, MSc, FRCPC; Jason P. Acker, MBA, PhD; Kumanan Wilson, MD, FRCPC; Greg Knoll, MD, MSc, FRCPC; Nadine Shehata, MD, MSc, FRCPC; Carl van Walraven, MD, MSc, FRCPC; Alan J. Forster, MD, MSc, FRCPC; Timothy Ramsay, PhD; Lauralyn A. McIntyre, MD, MSc, FRCPC; Dean A. Fergusson, MHA, PhD
Le rêve et la psychanalyse.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Recommendations for protection against viral hepatitis
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contempo: pediatrics
Authors: B. S. Shapiro
Journal: JAMA (1994)

<h3>In Reply.</h3> —We thank Shapiro et al for pointing out the importance of current issues in pediatrics and of critical interest for children's health and welfare. We appreciate their observations concerning our contribution to Contempo. However, we disagree with their assessment of what we should have done. I have been contributing to Contempo for almost a decade now and usually have followed the format of a survey of the discipline at that moment. This time, we believed that what was happening in genetics was not an isolated phenomenon, applying to only a few individuals, but had the potential for affecting the very fabric of medicine, pediatrics, and preventive medicine. Given the space limitations of a Contempo article and given the scant attention that these revolutionary and rapidly developing advances in genetic science and medicine have received in the professional pediatric literature, we felt it important to highlight them for the